Small Cap Gainers: CLDX, ORMP, ATEC
3:16 pm Monday, July 12th, 2021
Celldex Therapeutics, Inc. (NASDAQ: CLDX) provided updated data from its ongoing Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism. Among results, all 19 patients who received a single full dose of CDX-0195 experienced a clinical response to provocation testing; 18 of 19 experienced a complete response, and one experienced a marked partial response; responses, said co, were “rapid, profound, and durable and correlated with a depletion of skin mast cells”, and the safety profile was favorable. Shares of CLDX are up 24% to $40.20.
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) pushes higher on a spike in volume; the stock gains to two-week highs after touching down to one-month lows late last week. The stock s now up 13% to $13.90. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
Alphatec Holdings Inc (NASDAQ: ATEC) moved up 12% to $15.85 after the company announced certain preliminary Q2 results; co expects total quarterly revs, excluding the impact of EOS imaging, of $55.8-56.4 mln, representing growth of +88.2% to 90.2% yr/yr. Co cites “portfolio-wide momentum” for driving revs growth in the US, giving co confidence that its organic US revs growth will exceed +50% this year. At two-month highs.
